RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%

    NEXT STORY
    Immunoassay in R&D Market Value to Surpass USD 7,716.6 Million Revenue Mark by 2023 at 8.18 % CAGR, Says Market Research Future
    PREV STORY
    G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy

    CRESTWOOD, Ky., and WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) ...

    author_avatar
    NASDAQ Market News

    Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress

    author_avatar
    NASDAQ Market News

    BioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020

    author_avatar
    NASDAQ Market News